文献速递骨质疏松与钙磷/甲状旁腺

特立帕肽与地舒单抗在长期双膦酸盐治疗患者中的比较

Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

本研究基于美国两家学术医疗中心的电子病历,比较长期使用双膦酸盐后换用特立帕肽或地舒单抗的骨质疏松患者骨密度变化。结果显示,特立帕肽组腰椎年化骨密度变化比地舒单抗组高1.3%,但全髋和股骨颈分别低2.2%和1.1%。特立帕肽组髋部骨密度第一年出现短暂下降,2年内全髋无总体增加。

要点

  • 长期双膦酸盐后换用特立帕肽,腰椎骨密度增加优于地舒单抗。
  • 特立帕肽组全髋和股骨颈骨密度变化低于地舒单抗组。
  • 髋部骨折高风险患者换用特立帕肽需谨慎。

核心结论

  • 在长期使用双膦酸盐的患者中,换用特立帕肽相较于地舒单抗,腰椎骨密度增加更多,但全髋和股骨颈骨密度变化更低。
  • 特立帕肽组髋部骨密度第一年出现短暂下降,2年内全髋骨密度无总体增加。
  • 对于髋部骨折高风险患者,换用特立帕肽的决策应谨慎。

研究设计与样本

  • 观察性队列研究,使用美国两家学术医疗中心的电子病历数据。
  • 研究对象为年龄>45岁、使用双膦酸盐>1年后换用特立帕肽或地舒单抗的骨质疏松患者。
  • 特立帕肽组110例,地舒单抗组105例;平均年龄70岁,双膦酸盐使用中位时间7.0年。

主要发现

  • 与地舒单抗组相比,特立帕肽组腰椎年化骨密度变化高1.3%(95% CI 0.02, 2.7%)。
  • 特立帕肽组全髋年化骨密度变化比地舒单抗组低-2.2%(95% CI -2.9 to -1.5%)。
  • 特立帕肽组股骨颈年化骨密度变化比地舒单抗组低-1.1%(95% CI -2.1 to -0.1%)。
  • 特立帕肽组换药后第一年髋部骨密度出现短暂下降,2年内全髋骨密度无总体增加。

临床怎么用

  • 长期双膦酸盐治疗后选择换用特立帕肽或地舒单抗时,需权衡腰椎与髋部骨密度获益差异。
  • 对髋部骨折高风险患者,换用特立帕肽应谨慎评估。

局限性

  • 本研究为观察性队列研究,可能存在混杂因素。
  • 样本来自两家学术医疗中心,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Teriparatide and denosumab are effective treatments for osteoporosis and typically reserved as second-line options after patients have used bisphosphonates. However, limited head-to-head comparative effectiveness data exist between teriparatide and denosumab. OBJECTIVE: We compared changes in bone mineral density (BMD) between groups treated with teriparatide or denosumab after using bisphosphonates, focusing on the change in BMD while on either drug over 2 years. DESIGN: Observational cohort study using electronic medical records from two academic medical centers in the United States. PARTICIPANTS: The study population included osteoporotic patients >45 years who received bisphosphonates >1 year before switching to teriparatide or denosumab. OUTCOME MEASURES: Annualized BMD change from baseline at the lumbar spine, total hip, and femoral neck. RESULTS: Patients treated with teriparatide (n = 110) were compared with those treated with denosumab (n = 105); the mean (SD) age was 70 (10) years and median duration (interquartile range) of bisphosphonate use was 7.0 (5.6 to 9.7) years. Compared with denosumab users, teriparatide users had higher annualized BMD change at the spine by 1.3% (95% CI 0.02, 2.7%) but lower at the total hip by -2.2% (95% CI -2.9 to -1.5%) and the femoral neck by -1.1% (95% CI -2.1 to -0.1%). Those who switched to teriparatide had a transient loss of hip BMD for the first year, with no overall increase in the total hip BMD over 2 years. CONCLUSIONS: Among patients who use long-term bisphosphonates, the decision of switching to teriparatide should be made with caution, especially for patients at high risk of hip fracture.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lyu H, Zhao SS, Yoshida K, et al. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use. J Clin Endocrinol Metab. 2019. PMID: 31265071. doi:10.1210/jc.2019-00924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。